In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Jaroslav Cermak discusses new opportunities resulting from the utilization of experimental therapeutics for myelodysplastic syndromes (MDS).
Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?specialty=Hematology
© 2017 Imedex, LLC.